Recent Insider Transactions • Jul 30
Insider recently sold €3.9m worth of stock On the 28th of July, Susan Burwig sold around 8k shares on-market at roughly €527 per share. This transaction amounted to 11% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €194m more than they bought in the last 12 months. Duyuru • Jul 24
Medpace Holdings, Inc. Updates Earnings Guidance for the Year 2026 Medpace Holdings, Inc. updated earnings guidance for the year 2026. For the year, the company expects total revenue in the range of $2.805 billion to $2.885 billion, representing growth of 10.9% to 14% over 2025 total revenue of $2.53 billion. The company forecast 2026 net income in the range of $494 million to $514 million. Earnings per diluted share is now expected to be in the range of $17.25 to $17.95. Reported Earnings • Jul 23
Second quarter 2026 earnings released: EPS: US$4.31 (vs US$3.16 in 2Q 2025) Second quarter 2026 results: EPS: US$4.31 (up from US$3.16 in 2Q 2025). Revenue: US$707.3m (up 17% from 2Q 2025). Net income: US$121.4m (up 35% from 2Q 2025). Profit margin: 17% (up from 15% in 2Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 24% per year whereas the company’s share price has increased by 27% per year. New Risk • Jul 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Buy Or Sell Opportunity • Jul 08
Now 22% undervalued Over the last 90 days, the stock has risen 8.3% to €462. The fair value is estimated to be €590, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 24%. For the next 3 years, revenue is forecast to grow by 7.6% per annum. Earnings are also forecast to grow by 9.4% per annum over the same time period. Valuation Update With 7 Day Price Move • Jun 26
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to €457, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 21x in the Life Sciences industry in Europe. Total returns to shareholders of 108% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €574 per share. Duyuru • Jun 17
Medpace Holdings, Inc. to Report Q2, 2026 Results on Jul 22, 2026 Medpace Holdings, Inc. announced that they will report Q2, 2026 results After-Market on Jul 22, 2026 Duyuru • Jun 06
Medpace Holdings, Inc. Announces Appointment of Brad W. Hansman to Executive Vice President, Operations, Effective June 1, 2026 Effective June 1, 2026, Medpace Holdings, Inc. appointed Brad W. Hansman, age 43, to the position of Executive Vice President, Operations. In this role, Mr. Hansman shall perform the functions of the Company’s principal operating officer along with Susan E. Burwig, the Company’s Executive Vice President, Operations. Mr. Hansman joined the Company in April 2011 in Finance & Accounting and held various roles in Finance until July 2015. Since August 2015, Mr. Hansman has held various key leadership roles in operations including Executive Director, Vice President, and Senior Vice President overseeing study start-up, logistics, regulatory affairs, and medical writing. Prior to joining the Company, Mr. Hansman worked for Joseph Decosimo & Company, LLC as an Audit Supervisor from July 2008 to March 2011. Mr. Hansman started his career at Macy’s, Inc. where he held various auditor positions from July 2006 to June 2008. Mr. Hansman received his Bachelor of Business Administration in Accounting from Eastern Kentucky University and is a Certified Public Accountant (inactive). Mr. Hansman does not hold any public company directorships. Board Change • May 20
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. Independent Director Dani Zander was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Duyuru • Apr 23
Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2026 Medpace Holdings, Inc. provided earnings guidance for the year 2026. For the year, the company forecasts revenue in the range of $2.755 billion to $2.855 billion, representing growth of 8.9% to 12.8% over 2025 revenue of $2.530 billion. GAAP net income for full year 2026 is forecasted in the range of $487.0 million to $511.0 million. Based on forecasted 2026 revenue of $2.755 billion to $2.855 billion and GAAP net income of $487.0 million to $511.0 million, diluted earnings per share (GAAP) is forecasted in the range of $16.68 to $17.50. This guidance assumes a full year 2026 tax rate of 19.0% to 20.0%, interest income of $27.5 million, foreign exchange rates as of March 31, 2026, and 29.2 million diluted weighted average shares outstanding. Duyuru • Mar 25
Medpace Holdings, Inc. to Report Q1, 2026 Results on Apr 22, 2026 Medpace Holdings, Inc. announced that they will report Q1, 2026 results After-Market on Apr 22, 2026 Duyuru • Mar 17
Medpace Holdings, Inc., Annual General Meeting, May 15, 2026 Medpace Holdings, Inc., Annual General Meeting, May 15, 2026. Duyuru • Feb 10
Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year of 2026 Medpace Holdings, Inc. provides earnings guidance for the full year of 2026. For the period, the company expects revenue in the range of $2.755 billion to $2.855 billion, representing growth of 8.9% to 12.8% over 2025 revenue of $2.530 billion. GAAP net income is forecasted in the range of $487.0 million to $511.0 million, diluted earnings per share (GAAP) is forecasted in the range of $16.68 to $17.50. Duyuru • Jan 06
Medpace Holdings, Inc. to Report Q4, 2025 Results on Feb 09, 2026 Medpace Holdings, Inc. announced that they will report Q4, 2025 results After-Market on Feb 09, 2026 Duyuru • Oct 23
Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2025 Medpace Holdings, Inc. provided earnings guidance for the full year 2025. The Company forecasts 2025 revenue in the range of $2.480 billion to $2.530 billion, representing growth of 17.6% to 20.0% over 2024 revenue of $2.109 billion. GAAP net income for full year 2025 is forecasted in the range of $431.0 million to $439.0 million. Diluted earnings per share (GAAP) is forecasted in the range of $14.60 to $14.86. Duyuru • Sep 24
Medpace Holdings, Inc. to Report Q3, 2025 Results on Oct 22, 2025 Medpace Holdings, Inc. announced that they will report Q3, 2025 results After-Market on Oct 22, 2025 Duyuru • Jul 22
Medpace Holdings, Inc. Updates Earnings Guidance for the Full Year 2025 Medpace Holdings, Inc. updated earnings guidance for the full year 2025. For the year company expects revenue in the range of $2.420 billion to $2.520 billion, representing growth of 14.7% to 19.5% over 2024 revenue of $2.109 billion. GAAP net income for full year 2025 is forecasted in the range of $405.0 million to $428.0 million. Based on forecasted 2025 revenue of $2.420 billion to $2.520 billion and GAAP net income of $405.0 million to $428.0 million, diluted earnings per share (GAAP) is forecasted in the range of $13.76 to $14.53. Duyuru • Jun 24
Medpace Holdings, Inc. to Report Q2, 2025 Results on Jul 21, 2025 Medpace Holdings, Inc. announced that they will report Q2, 2025 results After-Market on Jul 21, 2025 Duyuru • Apr 22
Medpace Holdings, Inc. Provides Earnings Guidance for 2025 Medpace Holdings, Inc. provides earnings guidance for 2025. For the period, the Company forecasted 2025 revenue in the range of $2.140 billion to $2.240 billion, representing growth of 1.5% to 6.2% over 2024 revenue of $2.109 billion. GAAP net income for full year 2025 is forecasted in the range of $378.0 million to $402.0 million. Based on forecasted 2025 revenue of $2.140 billion to $2.240 billion and GAAP net income of $378.0 million to $402.0 million, diluted earnings per share (GAAP) is forecasted in the range of $12.26 to $13.04. Duyuru • Apr 03
Medpace Holdings, Inc., Annual General Meeting, May 16, 2025 Medpace Holdings, Inc., Annual General Meeting, May 16, 2025. Duyuru • Mar 19
Medpace Holdings, Inc. to Report Q1, 2025 Results on Apr 21, 2025 Medpace Holdings, Inc. announced that they will report Q1, 2025 results After-Market on Apr 21, 2025 Duyuru • Feb 11
Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2025 Medpace Holdings, Inc. provided earnings guidance for the year 2025. For the period, the company expects revenue in the range of $2.110 billion to $2.210 billion, representing growth of 0.0% to 4.8% over 2024 revenue of $2.109 billion. GAAP net income for full year 2025 is forecasted in the range of $378.0 million to $402.0 million. Based on forecasted 2025 revenue of $2.110 billion to $2.210 billion and GAAP net income of $378.0 million to $402.0 million, diluted earnings per share (GAAP) is forecasted in the range of $11.93 to $12.69. Duyuru • Jan 03
Medpace Holdings, Inc. to Report Q4, 2024 Results on Feb 10, 2025 Medpace Holdings, Inc. announced that they will report Q4, 2024 results After-Market on Feb 10, 2025 Valuation Update With 7 Day Price Move • Nov 07
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €333, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 21x in the Life Sciences industry in Europe. Total returns to shareholders of 73% over the past three years. Reported Earnings • Oct 22
Third quarter 2024 earnings released: EPS: US$3.11 (vs US$2.30 in 3Q 2023) Third quarter 2024 results: EPS: US$3.11 (up from US$2.30 in 3Q 2023). Revenue: US$533.3m (up 8.3% from 3Q 2023). Net income: US$96.4m (up 37% from 3Q 2023). Profit margin: 18% (up from 14% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth. Duyuru • Oct 22
Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2024 Medpace Holdings, Inc. provided earnings guidance for the full year 2024. For the period, the company expects revenue in the range of $2.090 billion to $2.130 billion, representing growth of 10.8% to 12.9% over 2023 revenue of $1.886 billion. GAAP net income is forecasted in the range of $376.0 million to $388.0 million. Diluted earnings per share (GAAP) is forecasted in the range of $11.71 to $12.09. Duyuru • Sep 26
Medpace Holdings, Inc. to Report Q3, 2024 Results on Oct 21, 2024 Medpace Holdings, Inc. announced that they will report Q3, 2024 results After-Market on Oct 21, 2024 New Risk • Jul 23
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.2% average weekly change). Significant insider selling over the past 3 months (€60m sold). Reported Earnings • Jul 23
Second quarter 2024 earnings released: EPS: US$2.85 (vs US$2.00 in 2Q 2023) Second quarter 2024 results: EPS: US$2.85 (up from US$2.00 in 2Q 2023). Revenue: US$528.1m (up 15% from 2Q 2023). Net income: US$88.4m (up 45% from 2Q 2023). Profit margin: 17% (up from 13% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has increased by 43% per year, which means it is tracking significantly ahead of earnings growth. Duyuru • Jul 23
Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2024 Medpace Holdings, Inc. provided earnings guidance for the full year 2024. The company forecasts 2024 revenue in the range of $2.125 billion to $2.175 billion, representing growth of 12.7% to 15.3% over 2023 revenue of $1.886 billion. GAAP net income for full year 2024 is forecasted in the range of $361.0 million to $383.0 million. Based on forecasted 2024 revenue of $2.125 billion to $2.175 billion and GAAP net income of $361.0 million to $383.0 million, diluted earnings per share (GAAP) is forecasted in the range of $11.24 to $11.93. This guidance assumes a full year 2024 tax rate of 15.0% to 16.0%, interest income of $24.0 million, and 32.1 million diluted shares outstanding. Duyuru • Jun 27
Medpace Holdings, Inc. to Report Q2, 2024 Results on Jul 22, 2024 Medpace Holdings, Inc. announced that they will report Q2, 2024 results After-Market on Jul 22, 2024 Recent Insider Transactions • Jun 10
Executive Vice President of Operations recently sold €2.8m worth of stock On the 5th of June, Susan Burwig sold around 8k shares on-market at roughly €369 per share. This transaction amounted to 51% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €20m. Susan has been a net seller over the last 12 months, reducing personal holdings by €6.3m. Recent Insider Transactions • May 30
Chairman & CEO recently sold €3.5m worth of stock On the 28th of May, August Troendle sold around 10k shares on-market at roughly €364 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €75m. August has been a net seller over the last 12 months, reducing personal holdings by €476m. Recent Insider Transactions • May 02
Chairman & CEO recently sold €6.3m worth of stock On the 30th of April, August Troendle sold around 17k shares on-market at roughly €375 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €75m. August has been a net seller over the last 12 months, reducing personal holdings by €425m. New Risk • Apr 24
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.1% average weekly change). Significant insider selling over the past 3 months (€318m sold). Duyuru • Apr 23
Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2024 Medpace Holdings, Inc. provided earnings guidance for the full year 2024. The Company forecasts 2024 revenue in the range of $2.150 billion to $2.200 billion, representing growth of 14.0% to 16.7% over 2023 revenue of $1.886 billion. GAAP net income for full year 2024 is forecasted in the range of $347.0 million to $369.0 million, diluted earnings per share (GAAP) is forecasted in the range of $10.79 to $11.47. Reported Earnings • Apr 23
First quarter 2024 earnings released: EPS: US$3.33 (vs US$2.35 in 1Q 2023) First quarter 2024 results: EPS: US$3.33 (up from US$2.35 in 1Q 2023). Revenue: US$511.0m (up 18% from 1Q 2023). Net income: US$102.6m (up 41% from 1Q 2023). Profit margin: 20% (up from 17% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has increased by 36% per year, which means it is tracking significantly ahead of earnings growth. Duyuru • Apr 04
Medpace Holdings, Inc., Annual General Meeting, May 17, 2024 Medpace Holdings, Inc., Annual General Meeting, May 17, 2024, at 09:00 US Eastern Standard Time. Agenda: To elect Fred B. Davenport, Jr. and Cornelius P. McCarthy III as Class II Directors to serve until the 2027 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified; to ratify the appointment of Deloitte & Touche LLP as company independent registered public accounting firm for the fiscal year ending December 31, 2024; to conduct an advisory vote to approve compensation for our named executive officers; to approve an amendment to the company's Amended and Restated Certificate of Incorporation to begin phasing out the company's classified Board of Directors so that directors up for election at and after the 2025 Annual Meeting of Stockholders will be elected annually; and to transact such other business as may properly come before the Annual Meeting or any continuation, postponement, or adjournment of the Annual Meeting by or at the direction of the Board of Directors of the company. Duyuru • Mar 29
Medpace Holdings, Inc. to Report Q1, 2024 Results on Apr 22, 2024 Medpace Holdings, Inc. announced that they will report Q1, 2024 results on Apr 22, 2024 Recent Insider Transactions • Feb 23
Chairman & CEO recently sold €23m worth of stock On the 20th of February, August Troendle sold around 64k shares on-market at roughly €361 per share. This transaction amounted to 1.0% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. August has been a net seller over the last 12 months, reducing personal holdings by €125m. Valuation Update With 7 Day Price Move • Feb 20
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to €355, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 25x in the Life Sciences industry in Europe. Total returns to shareholders of 180% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €374 per share. Reported Earnings • Feb 13
Full year 2023 earnings released: EPS: US$9.21 (vs US$7.57 in FY 2022) Full year 2023 results: EPS: US$9.21 (up from US$7.57 in FY 2022). Revenue: US$1.89b (up 29% from FY 2022). Net income: US$282.8m (up 15% from FY 2022). Profit margin: 15% (down from 17% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 9.9% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 28% per year whereas the company’s share price has increased by 31% per year. Recent Insider Transactions • Dec 19
Executive Vice President of Operations recently sold €3.5m worth of stock On the 15th of December, Susan Burwig sold around 12k shares on-market at roughly €279 per share. This transaction amounted to 45% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €25m. This was Susan's only on-market trade for the last 12 months. Buying Opportunity • Dec 06
Now 21% undervalued Over the last 90 days, the stock is up 2.4%. The fair value is estimated to be €320, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has grown by 30%. For the next 3 years, revenue is forecast to grow by 13% per annum. Earnings is also forecast to grow by 15% per annum over the same time period. Recent Insider Transactions • Nov 17
Chairman & CEO recently sold €20m worth of stock On the 16th of November, August Troendle sold around 75k shares on-market at roughly €260 per share. This transaction amounted to 1.3% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was August's only on-market trade for the last 12 months. Duyuru • Oct 25
Medpace Holdings, Inc. Provides Earnings Guidance for the Fiscal Year 2023 and 2024 Medpace Holdings, Inc. provided earnings guidance for the fiscal year 2023 and 2024. For the year 2023, the company expects revenue in the range of $1.870 billion to $1.890 billion, representing growth of 28.1% to 29.5% over 2022 revenue of $1.460 billion. GAAP net income for full year 2023 is forecasted in the range of $272.0 million to $276.0 million and diluted earnings per share (GAAP) is forecasted in the range of $8.54 to $8.66.For the year 2024, the company expects revenue in the range of $2.150 billion to $2.200 billion. New Risk • Oct 25
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Reported Earnings • Oct 24
Third quarter 2023 earnings released: EPS: US$2.30 (vs US$2.13 in 3Q 2022) Third quarter 2023 results: EPS: US$2.30 (up from US$2.13 in 3Q 2022). Revenue: US$492.5m (up 28% from 3Q 2022). Net income: US$70.6m (up 6.9% from 3Q 2022). Profit margin: 14% (down from 17% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 30% per year whereas the company’s share price has increased by 32% per year. Duyuru • Sep 27
Medpace Holdings, Inc. to Report Q3, 2023 Results on Oct 23, 2023 Medpace Holdings, Inc. announced that they will report Q3, 2023 results on Oct 23, 2023 Buying Opportunity • Sep 19
Now 20% undervalued Over the last 90 days, the stock is up 25%. The fair value is estimated to be €323, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 32%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings is also forecast to grow by 12% per annum over the same time period. Reported Earnings • Jul 25
Second quarter 2023 earnings released: EPS: US$2.00 (vs US$1.52 in 2Q 2022) Second quarter 2023 results: EPS: US$2.00 (up from US$1.52 in 2Q 2022). Revenue: US$460.9m (up 31% from 2Q 2022). Net income: US$61.1m (up 24% from 2Q 2022). Profit margin: 13% (in line with 2Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 32% per year whereas the company’s share price has increased by 30% per year. Duyuru • Jul 25
Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2023 Medpace Holdings, Inc. provided earnings guidance for the full year 2023. The company forecasts 2023 revenue in the range of $1.840 billion to $1.880 billion, representing growth of 26.0% to 28.8% over 2022 revenue of $1.460 billion. GAAP net income for full year 2023 is forecasted in the range of $256.0 million to $271.0 million. Based on forecasted 2023 revenue of $1.840 billion to $1.880 billion and GAAP net income of $256.0 million to $271.0 million, diluted earnings per share (GAAP) is forecasted in the range of $8.04 to $8.50. Duyuru • Jul 06
Medpace Holdings, Inc. to Report Q2, 2023 Results on Jul 24, 2023 Medpace Holdings, Inc. announced that they will report Q2, 2023 results After-Market on Jul 24, 2023 Buying Opportunity • Jun 22
Now 21% undervalued Over the last 90 days, the stock is up 21%. The fair value is estimated to be €255, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 20% over the last 3 years. Earnings per share has grown by 32%. For the next 3 years, revenue is forecast to grow by 11% per annum. Earnings is also forecast to grow by 12% per annum over the same time period. Reported Earnings • Apr 26
First quarter 2023 earnings released: EPS: US$2.35 (vs US$1.76 in 1Q 2022) First quarter 2023 results: EPS: US$2.35 (up from US$1.76 in 1Q 2022). Revenue: US$434.1m (up 31% from 1Q 2022). Net income: US$72.9m (up 19% from 1Q 2022). Profit margin: 17% (down from 19% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 32% per year whereas the company’s share price has increased by 34% per year. Duyuru • Feb 14
Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2023 Medpace Holdings, Inc. provided earnings guidance for the year 2023. For the year, the company expects revenue in the range of $1.690 billion to $1.750 billion, representing growth of 15.8% to 19.9% over 2022 revenue of $1.460 billion. GAAP net income is forecasted in the range of $245.0 million to $265.0 million. Based on forecasted revenue of $1.690 billion to $1.750 billion and GAAP net income of $245.0 million to $265.0 million, diluted earnings per share (GAAP) is forecasted in the range of $7.53 to $8.14. Reported Earnings • Feb 14
Full year 2022 earnings released: EPS: US$7.58 (vs US$5.06 in FY 2021) Full year 2022 results: EPS: US$7.58 (up from US$5.06 in FY 2021). Revenue: US$1.46b (up 28% from FY 2021). Net income: US$245.4m (up 35% from FY 2021). Profit margin: 17% (in line with FY 2021). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 32% per year whereas the company’s share price has increased by 34% per year. Duyuru • Jan 05
Medpace Holdings, Inc. to Report Fiscal Year 2022 Results on Feb 13, 2023 Medpace Holdings, Inc. announced that they will report fiscal year 2022 results at 4:00 PM, US Eastern Standard Time on Feb 13, 2023 Duyuru • Jan 04
Medpace Holdings, Inc. Announces Resignation of Thomas C. King to Board On December 31, 2022, Thomas C. King, a member of the Board of Directors of Medpace Holdings, Inc. notified the Company of his resignation from the Board, effective as of December 31, 2022. Mr. King’s resignation did not result from any disagreement with the Company on any matter relating to its operations, policies or practices. Recent Insider Transactions • Nov 18
CFO & Treasurer recently sold €440k worth of stock On the 16th of November, Kevin Brady sold around 2k shares on-market at roughly €220 per share. This transaction amounted to 40% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Kevin's only on-market trade for the last 12 months. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 1 highly experienced director. Independent Director Thomas King was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 26
Third quarter 2022 earnings released: EPS: US$2.13 (vs US$1.35 in 3Q 2021) Third quarter 2022 results: EPS: US$2.13 (up from US$1.35 in 3Q 2021). Revenue: US$383.7m (up 30% from 3Q 2021). Net income: US$66.0m (up 36% from 3Q 2021). Profit margin: 17% (in line with 3Q 2021). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has increased by 48% per year, which means it is tracking significantly ahead of earnings growth. Duyuru • Oct 26
Medpace Holdings, Inc. (NasdaqGS:MEDP) announces an Equity Buyback for $500 million worth of its shares. Medpace Holdings, Inc. (NasdaqGS:MEDP) announces a share repurchase program. Under the program, the company will repurchase up to $500 million worth of its common stock. Duyuru • Oct 25
Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2022 and 2023 Medpace Holdings, Inc. provided earnings guidance for the year 2022 and 2023. For the year 2022, the company expects revenue in the range of $1.440 billion to $1.460 billion, representing growth of 26.1% to 27.8% over 2021 revenue of $1.142 billion. GAAP net income for full year 2022 is forecasted in the range of $232.0 million to $236.0 million. Based on forecasted 2022 revenue of $1.440 billion to $1.460 billion and GAAP net income of $232.0 million to $236.0 million, diluted earnings per share (GAAP) is forecasted in the range of $6.88 to $7.00. This guidance assumes a full year 2022 tax rate of 16.0% to 17.0%, 33.7 million diluted weighted-average shares outstanding for 2022, and foreign exchange rates as of September 30, 2022.For the year 2023, the company expects revenue in the range of $1.680 billion to $1.740 billion. Duyuru • Sep 28
Medpace Holdings, Inc. to Report Q3, 2022 Results on Oct 24, 2022 Medpace Holdings, Inc. announced that they will report Q3, 2022 results at 4:00 PM, US Eastern Standard Time on Oct 24, 2022 Recent Insider Transactions • Sep 23
Chairman & CEO recently bought €15m worth of stock On the 20th of September, August Troendle bought around 94k shares on-market at roughly €155 per share. This transaction amounted to 1.3% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. August has been a buyer over the last 12 months, purchasing a net total of €25m worth in shares. Recent Insider Transactions • Sep 14
Chairman & CEO recently bought €10m worth of stock On the 12th of September, August Troendle bought around 63k shares on-market at roughly €165 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was August's only on-market trade for the last 12 months. Reported Earnings • Jul 26
Second quarter 2022 earnings released: EPS: US$1.52 (vs US$1.11 in 2Q 2021) Second quarter 2022 results: EPS: US$1.52 (up from US$1.11 in 2Q 2021). Revenue: US$351.2m (up 26% from 2Q 2021). Net income: US$49.4m (up 24% from 2Q 2021). Profit margin: 14% (in line with 2Q 2021). Over the next year, revenue is forecast to grow 14%, compared to a 12% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 31% per year and the company’s share price has also increased by 31% per year. Duyuru • Jul 26
Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2022 Medpace Holdings, Inc. provided earnings guidance for the full year 2022. The company forecasts 2022 revenue in the range of $1.405 billion to $1.435 billion, representing growth of 23.0% to 25.6% over 2021 revenue of $1.142 billion. GAAP net income for full year 2022 is forecasted in the range of $205.0 million to $215.0 million. Duyuru • Jul 08
Medpace Holdings, Inc. to Report Q2, 2022 Results on Jul 25, 2022 Medpace Holdings, Inc. announced that they will report Q2, 2022 results After-Market on Jul 25, 2022 Board Change • Jun 02
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Independent Director Thomas King was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Apr 27
First quarter 2022 earnings released: EPS: US$1.76 (vs US$1.21 in 1Q 2021) First quarter 2022 results: EPS: US$1.76 (up from US$1.21 in 1Q 2021). Revenue: US$330.9m (up 27% from 1Q 2021). Net income: US$61.3m (up 42% from 1Q 2021). Profit margin: 19% (up from 17% in 1Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 21%, compared to a 12% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 31% per year whereas the company’s share price has increased by 36% per year. Duyuru • Apr 26
Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2022 Medpace Holdings, Inc. provides earnings guidance for the full year 2022. The Company forecasts 2022 revenue in the range of $1.400 billion to $1.460 billion, representing growth of 22.6% to 27.8% over 2021 revenue of $1.142 billion. GAAP net income for full year 2022 is forecasted in the range of $204.0 million to $216.0 million. Diluted earnings per share (GAAP) is forecasted in the range of $5.72 to $6.06. Duyuru • Apr 07
Medpace Holdings, Inc., Annual General Meeting, May 20, 2022 Medpace Holdings, Inc., Annual General Meeting, May 20, 2022, at 09:00 US Eastern Standard Time. Agenda: To consider the election of Directors; to ratify the appointment of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2022; and to approve, on an advisory basis, the compensation of our named executive officers as disclosed in the proxy statement for the 2022 Annual Meeting. Valuation Update With 7 Day Price Move • Mar 19
Investor sentiment improved over the past week After last week's 16% share price gain to €150, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 47x in the Life Sciences industry in Europe. Total returns to shareholders of 197% over the past three years. Recent Insider Transactions • Feb 23
Lead Independent Director recently bought €64k worth of stock On the 17th of February, Fred Davenport bought around 500 shares on-market at roughly €128 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold €795k more in shares than they bought in the last 12 months. Valuation Update With 7 Day Price Move • Feb 22
Investor sentiment deteriorated over the past week After last week's 19% share price decline to €122, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 38x in the Life Sciences industry in Europe. Total returns to shareholders of 153% over the past three years. Reported Earnings • Feb 16
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: EPS: US$5.07 (up from US$4.07 in FY 2020). Revenue: US$1.14b (up 23% from FY 2020). Net income: US$181.8m (up 26% from FY 2020). Profit margin: 16% (in line with FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 25%, compared to a 26% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 32% per year whereas the company’s share price has increased by 35% per year. Duyuru • Feb 15
Medpace Holdings, Inc. Provides Consolidated Earnings Guidance for the Year 2022 Medpace Holdings, Inc. provided consolidated earnings guidance for the year 2022. For the year, the company expects revenue in the range of $1.400 billion to $1.460 billion, representing growth of 22.6% to 27.8% over 2021 revenue of $1.142 billion. GAAP net income for full year 2022 is forecasted in the range of $204.0 million to $216.0 million. Based on forecasted 2022 revenue and GAAP net income, diluted earnings per share (GAAP) is forecasted in the range of $5.35 to $5.67. Buying Opportunity • Jan 26
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 20%. The fair value is estimated to be US$189, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% per annum over the last 3 years. Earnings per share has grown by 34% per annum over the last 3 years. Reported Earnings • Oct 26
Third quarter 2021 earnings released: EPS US$1.36 (vs US$1.16 in 3Q 2020) The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: US$295.6m (up 28% from 3Q 2020). Net income: US$48.6m (up 18% from 3Q 2020). Profit margin: 16% (down from 18% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has increased by 58% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Jul 28
Second quarter 2021 earnings released: EPS US$1.11 (vs US$0.68 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: US$278.3m (up 36% from 2Q 2020). Net income: US$39.9m (up 66% from 2Q 2020). Profit margin: 14% (up from 12% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has increased by 43% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Apr 28
First quarter 2021 earnings released: EPS US$1.21 (vs US$0.80 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$260.0m (up 13% from 1Q 2020). Net income: US$43.3m (up 50% from 1Q 2020). Profit margin: 17% (up from 13% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has increased by 63% per year, which means it is tracking significantly ahead of earnings growth. Duyuru • Apr 27
Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2021 Medpace Holdings, Inc. provided earnings guidance for the year 2021. For the year, the company expects revenue to be in the range of $1.090 billion to $1.150 billion, representing growth of 17.7% to 24.2% over 2020 revenue of $925.9 million. GAAP net income for full year 2021 is forecasted in the range of $160.6 million to $167.6 million. Based on forecasted 2021 revenue of $1.090 billion to $1.150 billion and GAAP net income of $160.6 million to $167.6 million, diluted earnings per share (GAAP) is forecasted in the range of $4.24 to $4.42. Duyuru • Mar 11
Medpace Holdings, Inc. to Report Q1, 2021 Results on Apr 26, 2021 Medpace Holdings, Inc. announced that they will report Q1, 2021 results After-Market on Apr 26, 2021 Recent Insider Transactions • Mar 06
Executive Vice President of Operations recently sold €859k worth of stock On the 3rd of March, Susan Burwig sold around 6k shares on-market at roughly €138 per share. This was the largest sale by an insider in the last 3 months. Susan has been a seller over the last 12 months, reducing personal holdings by €2.2m. Reported Earnings • Feb 19
Full year 2020 earnings released: EPS US$4.07 (vs US$2.79 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: US$925.9m (up 7.5% from FY 2019). Net income: US$144.9m (up 45% from FY 2019). Profit margin: 16% (up from 12% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has increased by 64% per year, which means it is tracking significantly ahead of earnings growth. Analyst Estimate Surprise Post Earnings • Feb 19
Revenue beats expectations Revenue exceeded analyst estimates by 1.5%. Over the next year, revenue is forecast to grow 23%, compared to a 23% growth forecast for the Life Sciences industry in Germany. Is New 90 Day High Low • Feb 05
New 90-day high: €121 The company is up 20% from its price of €101 on 06 November 2020. The German market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €87.22 per share. Duyuru • Jan 28
Medpace Holdings, Inc.(NasdaqGS:MEDP) dropped from Russell 2000 Dynamic Index Medpace Holdings, Inc.(NasdaqGS:MEDP) dropped from Russell 2000 Dynamic Index Duyuru • Jan 06
Medpace Holdings, Inc. to Report Q4, 2020 Results on Feb 15, 2021 Medpace Holdings, Inc. announced that they will report Q4, 2020 results After-Market on Feb 15, 2021 Is New 90 Day High Low • Dec 02
New 90-day high: €109 The company is up 4.0% from its price of €105 on 03 September 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €72.78 per share. Reported Earnings • Oct 27
Third quarter earnings released Over the last 12 months the company has reported total profits of US$124.1m, up 33% from the prior year. Total revenue was US$896.1m over the last 12 months, up 8.8% from the prior year. Analyst Estimate Surprise Post Earnings • Oct 27
Third-quarter earnings released: Revenue beats expectations Third-quarter revenue exceeded analyst estimates by 3.0% at US$230.4m. Revenue is forecast to grow 17% over the next year, compared to a 17% growth forecast for the Life Sciences industry in Germany. Duyuru • Sep 04
Medpace Holdings, Inc. to Report Q3, 2020 Results on Oct 26, 2020 Medpace Holdings, Inc. announced that they will report Q3, 2020 results at 5:00 PM, Eastern Standard Time on Oct 26, 2020 Duyuru • Jul 05
Medpace Holdings, Inc.(NasdaqGS:MEDP) dropped from Russell 2000 Dynamic Index Medpace Holdings, Inc.(NasdaqGS:MEDP) dropped from Russell 2000 Dynamic Index 
